Lantern Pharma is trading 10% up at $1.10 in pre-market on October 2, 2026, following the close of its registered direct offering. - Announced October 1, the offering covered 3,669,725 shares or pre-funded warrants at $1.09 each. - It raised approximately $4 million upfront, with up to another $4 million possible from warrant exercises. - Shares closed at $1.00 on October 1; pre-market volume was not provided, and no separate October 2 pre-market catalyst was identified.